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ABSTRACT 
Stability plays an important role in drug development process. It explains several factors that affect the quality of a drug substance or drug products varies with 
time under the influence of environmental factors such as temperature, humidity and light. Stability studies play a vital role to decide the re-test period and 
shelf life for the drug substance and recommended storage conditions of API. ICH and EMEA guidelines define stability data package for new drug substance 
or drug product that is sufficient for a registration application within the three regions of the EC, Japan and United States.  
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INTRODUCTION 
It  is  considered  good  practice  to  test  the  stability  of  drug 
substances  according  to  the  International  Conference  on 
Harmonization  (ICH)  and  Committee  for  Proprietary 
Medicinal  Products  [CPMP]  guidelines,  The  purpose  of 
stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the 
influence  of  a  variety  of  environmental  factors  such  as 
temperature,  humidity,  and  light,  and  to  establish  a re-test 
period  for  the  drug  substance  or  a  shelf  life  for  the  drug 
product and recommended storage conditions. 
In a standard stability program, a stress study is first carried 
out to determine the drug substance's degradation path and to 
establish  suitable  analytical  methods.  Drug  substance 
stability studies are then conducted to define stability under 
long-term and accelerated storage conditions. 
In the next phase of the development plan, the drug substance 
is  formulated into  a  drug  product  and  compatibility  of  the 
drug  substance  with  excipients  and  container  parts  is  then 
tested. When suitable conditions are determined, long-term 
and accelerated studies commence with the drug product. The 
data  obtained  from  these  studies  are  used  to  define  the 
optimal storage conditions and corresponding retest period or 
shelf life for the drug substance. 
Objective of stability studies: 
The purpose of stability testing is to provide evidence on how 
the quality of a drug substance [API]  
· under the influence of a variety of environmental factors 
such as temperature, humidity, and light, and varies with 
time 
· to establish a re-test period for the API (drug substance)  
· to develop the understanding of the degradation pathway of 
the API which may influence the quality of drug product. 
COMMON  TERMINOLOGY  USED  DURING  THE 
STABILITY STUDIES 
What is a Commitment Batch? 
Production batches of a drug substance for which the stability 
studies  are  initiated  or  completed  post  approval  through  a 
commitment made in the registration application. 
What is Drug Substance? 
The unformulated drug substance that may subsequently be 
formulated with excipients to produce the dosage form. 
 
 
 
What is the meaning of Pilot scale batch? 
A batch of a drug substance manufactured by a procedure 
fully representative of and simulating that to be applied to a 
full production scale batch. 
What is the meaning of Primary Batch? 
A batch of a drug substance used in a formal stability study, 
from  which  stability  data  are  submitted  in  a  registration 
application for the purpose of establishing a re-test period or 
shelf life, respectively. However, a primary batch may be a 
production batch. 
What is the Production Batch? 
A batch of a drug substance manufactured at production scale 
by  using  production  equipment  in  a  production  facility  as 
specified in the application. 
What is significant change? 
 Failure to meets its specification or 5% assay variation from 
its initial value. 
What is Re-test Date? 
The date after which samples of the drug substance should be 
examined to ensure that the material is still in compliance 
with  the  specification  and  thus  suitable  for  use  in  the 
manufacture of a given drug product. 
What is Re-test period 
The  period  of  time  during  which  the  drug  substance  is 
expected to remain within its specification and, therefore, can 
be used in the manufacture of a given drug product, provided 
that  the  drug  substance  has  been  stored  under  the  defined 
conditions.  After  this  period,  a  batch  of  drug  substance 
destined for use in the manufacture of a drug product should 
be re-tested for compliance with the specification and then 
used immediately.  
A batch of drug substance can be re-tested multiple times and 
a different portion of the batch used after each re-test, as long 
as it continues to comply with the specification.   
WHAT  IS  CLIMATIC  ZONES  AND  HOW  THE 
STABILITY  CONDITIONS  [TEMPERATURE  AND 
RELATIVE HUMIDITY] ARE ESTABLISHED BASED 
ON THE CLIMATIC ZONES 
The four zones in the world that are distinguished by their 
characteristic  prevalent  annual  climatic  conditions.  This  is 
based on the concept described by W. Grimm (Drugs Made 
in Germany, 28:196-202, 1985 and 29:39-47, 1986).  
Climatic zones 
–  Partition  of  the  world  into  three  temperature  classes 
based on kinetic averaging of monthly temperatures, & Agarwal Vipul et al: Stability Testing of API 
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subdivision of the hottest class into predominantly wet or 
predominantly dry 
–  Zones (Futscher & Schumacher 1972): 
•  I   Temperate (21ºC/45%RH) 
•  II  Subtropical (25ºC/60%RH with possibly high RH) 
•  III  Hot & dry (30ºC/35%RH) 
•  IV  Hot & wet (30ºC/70%RH) 
–  The temperatures above are kinetic averages 
International Climatic Zones & Conditions results are 
tabulated below:
 
Climatic Condition  Zone-I 
Temperature 
Zone-II 
Mediterranean 
(sub-tropical) 
Zone-III 
Hot / dry or 
Hot/moderate RH 
Zone-IV 
Very hot / 
humidity 
Mean Annual Temp  < 20°C  20.5-24°C  >24°C  >24°C 
Kinetic Mean Temp  21°C  26°C  31°C  31°C 
Mean Annual RH  45%  60%  40%  70% 
 
STABILITY TESTING CONDITIONS (Zone I and II): 
Long-term conditions   : 25°C ± 2°C/60% RH ± 5%  
Accelerated conditions   : 40°C ± 2°C/75% RH ± 5% 
Intermediate conditions   : 30°C ± 2°C/65% RH ± 5%    
STABILITY TESTING CONDITIONS (Zone III and 
IV):  
Long-term conditions   : 30°C ± 2°C/65% RH ± 5% RH  
Accelerated conditions   : 40°C ± 2°C/75% RH ± 5% 
No  intermediate  storage  conditions  for  stability  studies  are 
recommended for climatic Zone III and IV. Therefore, the 
intermediate storage conditions are not relevant.
1,2 
STRESS TESTING 
Stress testing can help identity the likely degradation 
products which can help to establish.  
· The degradation pathways.[ i.e degradation impurities and 
based  on  these  studies  the  Pharma  professional  can 
understand  how  the  Drug  substance    will  behave  during 
stability studies and how the product is stored in different 
environmental conditions]. 
· The intrinsic stability of the molecule. 
· Validate  the  stability  indicating  power  of  the  analytical 
procedures used.  
Stress testing is to be carried out on a single batch. It should 
include the effect of temperature i.e. Testing at 50/60°C (i.e 
10°C  increment)  above  that  accelerated  testing,  Humidity 
(75% or greater) where appropriate oxidation & photolysis on 
the drug substance has to be performed.  
To achieve the objective of stress study, Stress study of the 
API is to be performed in several conditions  
a.  Stress  study  in  oxidation  condition  by  using  Hydrogen 
peroxide  
b.  Stress  study  in  acidic  condition  by  using  Hydrochloric 
acid. 
c.  Stress  study  in  alkali  condition  by  using  Sodium 
Hydroxide. 
d.  Stress  study  by  heat  treatment  by  using  the  80°C 
temperature for 48 hours. 
e.  Stress  study  in  Sunlight  by  taking  in  account  the  ICH 
Q1B guideline 
If the significant levels of impurities are not present in the 
sample  of  API  then  a  particular  level  of  impurities  are  to 
spike in the stample and stress study is to performed for the 
aforementioned  conditions  to  understand  the  degradation 
pathways for the API. 
Photo  stability  testing  should  be  an  integral  part  of  stress 
testing.
1, 2 
Examining  degradation  products  under  stress  conditions  is 
useful in establishing degradation pathways and developing 
and validating suitable analytical procedures.  However, it is 
not necessary to identify all the impurities in stress studies for 
all but it is necessary to demonstrate that they are not formed 
under accelerated or long term storage conditions. 
The peak purity is one of the important criteria which is to be 
considered  during  stress  study  to  ensure  that  there  is  no 
interference of the other impurities peak with the main peak 
of API. 
Moreover during stress study the time period for each test 
should  not  be  short  because  no  large  degradation  will  be 
observed in the short period. In addition to this strengthening 
of the test conditions to make sure the height or peak area of 
principal peak is decreased up to 20% during stress study. 
SELECTION OF BATCHES 
Data from formal stability studies should be provided on at 
least  three  primary  batches  of  the  drug  substance.  The 
batches should be manufactured to a minimum of pilot scale 
by  the  same  synthetic  route  as,  and  using  a  method  of 
manufacture and procedure that simulates the final process to 
be used for, production batches.  The overall quality of the 
batches of drug substance placed on formal stability studies 
should be representative of the quality of the material to be 
made on a production scale.  
Following points are to considered during submission of the 
information  in  the  registration  dossier  to  the  International 
Regulatory Agencies 
a.  Data from 3 primary batches required (Batch number, 
date of manufacturing and size of each batch should be 
stated). 
b.  Primary batches could be from pilot / plant scale. 
c.  Plant / Pilot batches should be similar (process, 
equipment, route should be similar). 
CONTAINER CLOSURE SYSTEM 
Container closure is the sum of packaging components that 
together contain and protect the drug substance. This includes 
primary  packaging  components  and  secondary  packaging 
components. 
The  stability  studies  should  be  conducted  on  the  drug 
substance packaged in a container closure system that is the 
same as or simulates the packaging proposed for storage and 
distribution. 
Packaging for API 
Primary packaging material 
Generally  Low  density  polyethylene  bag  EU  (LDPE  bag) 
with twist tied with a plastic fastener is used as a primary 
packaging  material.  The  grade  of  the  primary  packaging 
material  should  complies  with  EU  Directive  No. 
2002/72/EEC  and  clause  #  3.2.2  and  clause  #  3.1.3  of 
European Pharmacopoeia level of plastic additives phenolic 
antioxidants,  non  phenolic  antioxidants  and  amides  and 
sterates    should  be  well  below  the  prescribed  level  in 
Pharmacopoeias.  Primary  packaging  material  should  also Agarwal Vipul et al: Stability Testing of API 
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comply  with  FDA  regulations  like  CFR  title  21.177.1520, 
olefin polymer. 
Secondary Packaging material 
Generally Triple laminated aluminum bag or LDPE black bag 
with heat sealed or twist tied are used as a second packaging 
material. 
Tertiary packaging material:  
HDPE Drum is used as a tertiary packaging material.
3,4 
STABILITY SPECIFICATION 
Specification – Release specification 
The  combination  of  physical,  chemical,  biological,  and 
microbiological tests and acceptance criteria that determine 
the suitability of a drug product at the time of its release. 
Specification – stability specification 
The  combination  of  physical,  chemical,  biological,  and 
microbiological tests and acceptance criteria that determine 
the  suitability  of  a  drug  substance  throughout  its  re-test 
period,  or  that  a  drug  product  should  meet  throughout  its 
shelf life. 
Note  :  Generally  release  and  stability    specification  are 
different, in these case API manufacturer should confirm that 
analytical  method  are  same  and    stability  results  obtained 
during the stability studies  are in compliance with the release 
specification and there is no out of specification is observed. 
Stability specification should have the following 
information’s 
· List of Tests. 
· Validated testing procedure. 
· Acceptance criteria ( at the time of release/shelf life) 
· Impurities. 
· Micro limits [If API is sterile in nature]. 
· Stability studies should include testing of those attributes of 
the  drug  substance  that  are  susceptible  to  change  during 
storage and are likely to influence quality, safety, and/or 
efficacy.  
· The testing should cover: chemical, physical, biological & 
microbiological parameters. 
· Validated stability-indicating analytical procedures should 
be applied.  
· The appropriate physical, chemical and microbial properties 
of the product susceptible to change during storage should 
be determined over the period of the proposed in-use shelf 
life. 
· If  possible,  testing  should  be  performed  at  intermediate 
time points and at the end of the proposed in-use shelf life 
on  the  final  remaining  amount  of  the  product  in  the 
container. 
Physical test: Description, colour, clarity, particle size etc. 
Chemical test: Residue on ignition, Heavy metal, Loss on 
drying/Water,  pH,  Specific  optical  rotation,  related 
substances, Assay and Residual solvents. 
Microbial test: Total viable count, sterility, BET.  
TESTING FREQUNCY 
For long term stability studies, stability samples are to be 
analyzed every three months for the first year, every six 
month for second year. Annually thereafter through the 
proposed re-test period. 
For accelerated storage condition, stability samples are to be 
analyzed  a  miminum  of  three  time  points  [eg.  0,  3  and 6 
months].  A  six  months  study  is  acceptable  for  accelerated 
storage conditions by various international authorities for the 
registration dossier. 
For Intermediate stability studies, stability samples are to be 
analyzed a minimum of  four time points [eg.: 0, 3, 6,9,12 
months]  if significant changes are observed at accelerated 
storage condition.  
STORAGE CONDITIONS  
General case 
Study  Storage Condition  Minimum time 
period covered by 
data at submission 
Long Term*  25±2°C/60 ±5%RH  12 months 
Intermediate**  30±2°C/65 ±5%RH  6 months 
Accelerated  40±2°C/75 ±5%RH  6 months 
*It is up to the applicant to decide whether long term stability 
studies are performed at 25 ± 2°C/60% RH ± 5% RH or 30°C 
± 2°C/65% RH ± 5% RH.  
**If 30°C ± 2°C/65% RH ± 5% RH is the long-term 
condition, there is no intermediate condition. 
Any “significant change” occurs at any time during 6 months 
at  accelerated  storage  conditions.  Additional  testing  at 
intermediate  storage  condition  should  be  conducted  and 
evaluated against significant change criteria. Testing at the 
intermediate storage condition should include all tests, unless 
otherwise justified. 
“Significant change” for a drug substance is defined as failure 
to meet its specification. 
Drug substances intended for storage in a refrigerator 
Study  Storage Condition  Minimum time period covered by data at 
submission 
Long Term  5°C ±3°C  12 months 
Accelerated  25°C±2°C/60% RH ±5%RH  6 months 
 
If significant change occurs between 3 and 6 months’ testing at the accelerated storage condition, the proposed re-test period 
should be based on the real time data available at the long term storage condition. 
If significant change occurs within the first 3 months’ testing at the accelerated storage condition, a discussion should be 
provided to address the effect of short term excursions outside the label storage condition, e.g., during shipping or handling.  
 
Drug substances intended for storage in a freezer 
Study  Storage Condition  Minimum time period covered by data at 
submission 
Long Term  -20°C ± ± ± ±5°C  12 months 
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There is no accelerated study for above case. 
Drug substances intended for storage below -20°C  
Drug substances intended for storage below -20°C should be 
treated on a case-by-case basis.  
Any “significant change” occurs during 6 months accelerated 
study. Additional testing at intermediate storage should be 
conducted. 
“Significant change” for a drug substance is defined as failure 
to meet its specification.
3,4,5 
STABILITY COMMITMENT 
·  When Initial long term data on primary batches may not 
cover the proposed re-test period granted at the time of 
approval,  a  commitment  should  be  made  to  continue 
  the   stability  studies,  post  approval  studies  in 
order to firmly establish the re-test period. If long-term 
batches cover the proposed retest period then commitment 
is considered unnecessary. 
·  If the submission includes data from stability studies on at 
least three production batches, a commitment should be 
made to continue these studies through the proposed re-
test period. 
·  If  submission  of  the  less  than  3  production  batches,  a 
commitment is  made  to  continue  the  long term  studies 
during  the  proposed  shelf  life  and  place  additional 
production  batches  on  long  term  studies  through  the 
proposed shelf life. 
·  If  submission  does  not  include  stability  data  on 
production batches, a commitment should   be 
made  to  place  first  3  production  batches  on  long  term 
studies through the proposed re-test period. 
EVALUATION  OF  STABILITY  DATA  TO 
ESTABLISH RETEST PERIOD/SHELF LIFE 
The  main  purpose  for  evaluation  to  establish  the  re-test 
period, applicable to all future batches of the drug substance 
manufactured  under  similar  circumstances.  The  degree  of 
variability of individual batches affects the confidence that a 
future  production  batch  will  remain  within  specification 
throughout the assigned re-test period. 
Extrapolation of data 
If  real  time  data  are  supported  by  results  from  studies 
conducted  under  accelerated  or  intermediate  storage 
conditions,  the re-test  period  may  be  extended  beyond  the 
end of real time studies. 
The extrapolated retest period may be up to twice, but should 
not be more than 12 months beyond the period covered by 
real time data, depending on the change over time, variability 
of data observed, proposed storage conditions and extent of 
statistical analyses performed. 
 
Example for assigning the re-test period or shelf life is given below: 
Sr. No.  Stability condition  X = Period covered by 
long-term data 
Y= Proposed retest period or 
shelf life 
01.  Accelerated  
(6 months OK) 
Long Term 
(9 months) 
Y=2x 
Shelf life/re-test date is 18 months. 
Accelerated  
(6 months OK) 
Long Term 
(12 months OK) 
Y=2x 
Shelf life/re-test date is 24 months. 
Accelerated  
(6 months OK) 
Long Term 
(18 months OK) 
Y=x+12 
Shelf life/re-test date is 30 months. 
Accelerated  
(6 months OK) 
Long Term 
(24 months OK) 
Y=x+12 
Shelf life/re-test date is 36 months. 
Accelerated  
(6 months OK) 
Long Term 
(36 months OK) 
Y=x 
No extrapolation beyond 36 
months. 
02.   Accelerated  
(6 months not OK) 
Intermediate 
(12 months OK) 
Y=1.5x 
Shelf life/re-test date is18 months. 
Accelerated  
(6 months not OK) 
Intermediate 
(9 months OK) 
Y=1.5x 
Shelf life/re-test date is 13.5 
months. 
Accelerated  
(6 months not OK) 
Intermediate 
(9 months not OK) 
& if long term 
(9 months OK) 
Y=x+3 
Shelf life/re-test date is12 months. 
Accelerated  
(3 months not OK) 
Intermediate  
(12 months OK) 
& Long Term  
(12 months OK) 
Y=1.5x 
(not exceeding x+6 months) 
Shelf life/retest date: 18months 
Accelerated 
(6 months not OK) 
Long Term  
( 6 months OK) 
Y=2x 
(not exceeding x+12 months) 
Shelf life/retest date: 12 months 
 
LABELING CONSIDERATION FOR DRUG SUBSTANCE: 
Following point’s are to be considered for the storage statement on labels: 
·  A storage statement should be based on the stability evaluation. 
·  Avoid use of “ambient condition” or “Room temperature” 
·  Need direct link between the label storage statement & the demonstrated stability. 
·  A retest period for drug substance should be derived from stability information and displayed on the container label. 
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Testing condition  Required labeling statement  Additional labeling statement, 
where relevant. 
25±2°C/60 ±5%RH 
40±2°C/75 ±5%RH 
[If stability results are within the 
specified limits] 
Does not require any special storage 
conditions. 
Do not refrigerate or freeze. 
25±2°C/60 ±5%RH 
30±2°C/65 ±5%RH 
[If stability results are within the 
specified limits] 
Do not store above 30°C 
Or Store below 30°C 
Do not refrigerate or freeze. 
25±2°C/60 ±5%RH 
(long term) 
[If stability results are within the 
specified limits] 
Do not store above 25°C 
Or Store below 25°C 
Do not refrigerate or freeze. 
5±3°C (long term) 
[If stability results are within the 
specified limits] 
Store in refrigerator  Do not freeze 
Below zero 
[If stability results are within the 
specified limits] 
Store in a freezer    --- 
 
Other specific storage conditions 
Sr. No.  Storage Problem  Additional labeling statements* depending on the packaging 
1  Sensitivity to moisture.  Keep the container*** tightly closed. 
2  Sensitivity to moisture.  Store in the original package. 
3  Sensitivity to light.**  Store in the original package. 
4  Sensitivity to light.**  Keep the container*** in the outer carton. 
 
An explanation for the labeling statement should be given in 
the package leaflet and on the outer packaging, where space 
permits. 
**Details  of  evaluation  and  included  in  the  committee  for 
proprietary medicinal products (CPMP) / ICH guideline on 
photo stability testing. 
***  The actual name  of  the  container  should  be  used,  eg. 
Bottle, blister.
5,6 
PHOTOSTABILITY 
The  intrinsic  photostability  characteristics  of  new  drug 
substances and products should be evaluated to demonstrate 
that,  as  appropriate,  light  exposure  does  not  result  in 
unacceptable  change.    Normally,  photo  stability  testing  is 
carried  out  on  a  single  batch  of  material.  A  systematic 
approach to photostability testing is recommended covering, 
as appropriate, studies such as:  
i)  Tests on the drug substance;  
ii)  Tests on the exposed drug product outside of the  
immediate pack; and if necessary ;  
iii) Tests on the drug product in the immediate pack; and if 
necessary;  
iv) Tests on the drug product in the marketing pack.  
Light Source:  
The  light  sources  described  below  may  be  used  for 
photostability testing. The applicant should either maintain an 
appropriate  control  of  temperature  to  inimize  the  effect  of 
localized temperature changes or include a dark control in the 
same environment unless otherwise justified.  
Option 1 
Any light source that is designed to produce an output similar 
to  the  D65/ID65  emission  standard  such  as  an  artificial 
daylight fluorescent lamp combining visible and ultraviolet 
(UV) outputs, xenon, or metal halide lamp.  
 
D 65 = Out door; ID 65 = Indoor 
For a light source emitting significant radiation below 320 
nm, an appropriate filter(s) may be fitted to eliminate such 
radiation.  
Option 2 
Sample should be exposed to both the cool white fluorescent 
and near ultraviolet lamp. 
01. A cool white fluorescent lamp designed to produce an 
output similar to that specified in ISO 10977(1993) ;  
02.  A near UV fluorescent lamp having a spectral 
distribution from 320 nm to 400 nm with a maximum 
energy emission between 350 nm and 370 nm; a 
significant proportion of UV should be in both bands of 
320 to 360 nm and 360 to 400 nm.    
Procedure 
For confirmatory studies, samples should be exposed to light 
providing an overall illumination of not less than 1.2 million 
lux hours and an integrated near ultraviolet energy of not less 
than 200 watt hours/square meter to allow direct comparisons 
to be made between the drug substance and drug product.  
Samples  may  be  exposed  side-by-side  with  a  validated 
chemical  actinometric  system  to  ensure  the  specified  light 
exposure is obtained, or for the appropriate duration of time 
when  conditions  have  been  monitored  using  calibrated 
radiometers/lux meters. If protected samples (e.g., wrapped in 
aluminum  foil)  are  used  as  dark  controls  to  evaluate  the 
contribution  of  thermally  induced  change  to  the  total 
observed  change,  these  should  be  placed  alongside  the 
authentic sample.
6,7,8 
Presentation of samples:
 
Care  should  be  taken  to  ensure  that  the  physical 
characteristics  of  the  samples  under  test  are  taken  into 
account and efforts should be made, such as cooling and/or 
placing the samples in sealed containers, to ensure that the 
effects of the changes in physical states such as sublimation, 
evaporation or melting are minimized.  All such precautions 
should be chosen to provide minimal interference with the 
exposure  of  samples  under  test.    Possible  interactions Agarwal Vipul et al: Stability Testing of API 
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between the samples and any material used for containers or 
for  general  protection  of  the  sample,  should  also  be 
considered and eliminated wherever not relevant to the test 
being carried out. As a direct challenge for samples of solid 
drug substances, an appropriate amount of sample should be 
taken  and  placed  in  a  suitable  glass  or  plastic  dish  and 
protected  with  a  suitable  transparent  cover  if  considered 
necessary.  Solid drug substances should be spread across the 
container to  give  a  thickness  of  typically  not  more  than 3 
millimeters.    Drug  substances  that  are  liquids  should  be 
exposed in chemically inert and transparent containers.   
Analysis of samples: 
At  the  end  of  the  exposure  period,  the  samples  should  be 
examined  for  any  changes  in  physical  properties  (e.g., 
appearance, clarity, or color of solution) and for assay and 
degradants by a method suitably validated for products likely 
to  arise  from  photochemical  degradation  processes.  Where 
solid drug substance samples are involved, sampling should 
ensure that a representative portion is used in individual tests.  
Similar sampling considerations, such as homogenization of 
the entire sample, apply to other materials that may not be 
homogeneous  after  exposure.  The  analysis  of  the  exposed 
sample should be performed concomitantly with that of any 
protected samples used as dark controls if these are used in 
the test. 
9,10 
CONCLUSION 
From  the  above  work  it  can  be  concluded  a  successful 
stability study will establish the retest period and shelf life for 
drug  substance  and  appropriate  storage  conditions.  Every 
manufacturer of the API should perform the stability studies 
as per the ICH/EMEA guidelines for USA, Europe and Japan 
region  and  understand  the  regulatory  requirements  versus 
scientific  requirements.  It  is  the  responsibility  of  the  API 
manufacturer to choose the correct storage condition and re-
test  date  so  that  impact  on  drug  product  quality  can  be 
minimized wrt degradation impurities. 
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